The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The company had achieved the highest "A" rating in Climate Change
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Granules India receives 1 observation from USFDA for Chantilly facility
Subscribe To Our Newsletter & Stay Updated
